Please assess the completion status of the following clinical trial:

Trial Title: Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective CABG surgery.~* Signed, documented informed consent prior to admission to the study.~Exclusion Criteria:~* Unstable angina, requiring intervention or CABG \<24 hrs after screening.~* Decompensated congestive heart failure.~* Chronic, persistent, paroxysmal atrial fibrillation.~* Uncorrected significant valvular heart disease~* Known hypersensitivity to the study drug~* Left ventricular dysfunction (ejection fraction \<35%)~* Use of anti-arrhythmic drugs other than beta blockers~* Non-cardiac illness with a life expectancy of less than 1 year~* Bleeding diathesis or history of coagulopathy~* Significant renal and liver insufficiency~* Significant thyroid, pulmonary disease~* Uncontrolled diabetes mellitus~* Patients on anti-arrhythmic drugs~* Patients with pacemaker~* Patients unable to provide/sign informed consent.~* Patients currently taking marine based omega-three fish oil supplements.~* Disturbances in lipid metabolism, serum triglyceride value \>3 mmol/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CABG and intralipid infusion (Type: PLACEBO_COMPARATOR): Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
- CABG and omega-3 fatty acid infusion (Type: ACTIVE_COMPARATOR): Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)

Based on this trial design, predict the completion outcome and termination type (if applicable).